{
    "nct_id": "NCT05301283",
    "official_title": "Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma",
    "inclusion_criteria": "* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* For women of childbearing potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 52 weeks after the end of radiation.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner 52 weeks after radiation.\n* Agreement to adhere to Lifestyle Considerations (as outlined in protocol) throughout study duration.\n* Pathologically (histologically or cytologically) proven diagnosis of high-grade (grade 2 or 3) Soft Tissue Sarcoma (STS) of the deep trunk and/or extremity. Clinical evidence should be documented, and may consist of pathology or imaging, and should be sufficient to estimate the size of the primary (for T stage)\n* Primary site deemed resectable prior to the start of trial\n* American Joint Committee on Cancer (AJCC) 8th edition staging T1-4 N0 M0, no evidence of distant metastases\n* Patients must have clinically or radiographically evident measurable disease at the primary site.\n* Pre-Radiation Therapy (RT) MRI within 4 weeks of the start of RT.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 3.\n* Deemed a surgical candidate\n* Participant agrees to blood and plasma preservation for future analysis.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Contraindications to an MRI\n* Positive urine pregnancy test\n* Gross total excision of primary STS, including an unplanned excision\n* Superficial sarcoma located primarily in the subcutaneous or cutaneous tissue\n* Prior radiation to the region of the study cancer that would result in overlap of radiation therapy fields.\n* Participants with a medical condition or social situation that, at the discretion of the principal investigator, would preclude them from completion of the trial.",
    "miscellaneous_criteria": ""
}